Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.

Mihir D BhattNeha ParmarJo-Ann FowlerAnthony K C ChanUma H Athale

Published in: Pediatric blood & cancer (2018)

Ability to administer full-dose LMWH, expected bleeding rate, and completion of asparaginase doses while on ACT suggest full-dose ACT is feasible and safe in children with ALL/LL who develop TE during DFCI ALL consortium therapy protocols.

Keyphrases

acute lymphoblastic leukemia
young adults
atrial fibrillation
papillary thyroid
squamous cell carcinoma
venous thromboembolism
stem cells
mesenchymal stem cells
acute myeloid leukemia
lymph node metastasis
newly diagnosed